The NHS has begun offering a "life-changing" drug to young children with a common allergy.
Allergies in young children can have the potential to cause worrying health problems and may be difficult to manage for some people.
Generally speaking, symptoms of food allergies tend to involve symptoms such as an itchy sensation in the mouth, throat or ears, hives, swelling around the lips, eyes or tongue and sometimes vomiting.
Food allergies are particularly troublesome when they cause anaphylaxis.
Sufferers of this may experience dizziness, breathing difficulties or trouble swallowing or speaking.
Allergic reactions happen when the body's immune system mistakenly treats the proteins found in a certain food as a threat.
When a drug comes along that can treat this, it is a welcome development, particularly for common allergies like a peanut allergy.
So what is the new drug and who does it help?
What is the new peanut allergy drug and how does it work?
The new drug will help children with peanut allergies and is known as "Palforzia".
It has already been available in the US and now the NHS has secured a deal for its use.
The drug works by giving the receiver tiny doses of the peanut protein that increase gradually from 0.5 mg to 6 mg, though the makers stress that it is not a cure and those with the allergy should still avoid eating peanuts and carry their adrenaline injection.
According to AllergyUK: "Peanuts are a common cause of food allergy, caused when the immune system reacts to the protein found in peanuts.
"Peanut allergy affects around 2% (one in 50) of children in the UK and has been increasing in recent decades.
"It usually develops in early childhood but, occasionally, can appear in later life.
"Peanut allergy tends to be persistent and only approximately 1 in 5 children outgrow their allergy, usually by the age of 10."
Will it help?
The drug is an oral treatment and will be available to up to 600 children aged four to 17 in the first year and 2,000 the year after.
Sophie Pratt's nine-year-old daughter Emily was part of the clinical trial and was delighted with the results.
Sophie told PA Media: "The treatment we received has meant that Emily is free from limits and the fear that the tiniest mistake could put her life at risk, and it has removed all the tension and worry that the simple act of eating loomed over us every day."
A study by Imperial College London found that, of the 187 people who dies from anaphylaxis in the UK between 1992 and 2018, at least 86 had a peanut allergy, around 46%.
